Resources

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and global license agreement.

Washington’s shifting policy landscape continues to cause uncertainty, while the UK is staying calm. Join our webinar this Thursday to hear how we’re engaging with international partners and government to ensure the UK voice is heard and our sector remains robust.

Amid ongoing geopolitical uncertainty, the UK life sciences ecosystem is keeping calm and carrying on.

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapy products for the treatment of multiple cancers, announces a partnership with the NHS Cancer Vaccine Launch Pad (CVLP) to fast-track access for NHS patients into the fourth cohort of the Company’s Phase 2 clinical SCOPE study. 

Change is happening fast for our sector at the moment, and I expect to see big calls from the UK government as it responds to global events this week.

In this blog, BIA member Brainomix, following its series C round, answers questions on the company's origins and future trajectory.

Oligos explainer: A new frontier in precision medicine, highlights the transformative potential of oligonucleotide therapies. These precision medicines, which use short DNA or RNA molecules to target specific genes, offer groundbreaking solutions for diseases previously deemed untreatable, from rare genetic disorders to cancer.

Emerson partners with biopharmaceutical companies to drive innovation, efficiency, and compliance in life sciences manufacturing through cutting-edge automation and process expertise.

Following a number of ‘firsts’ for Stablepharma during 2024, we spoke with Ozgur Tuncer, CEO and Executive Director about a year that has accelerated the commercialisation of the world’s first fridge-free vaccine, SPVX02, for the prevention of Tetanus and Diphtheria.

The 2024 Bionow Awards dinner marked an exceptional evening of recognition and celebration, as 342 distinguished guests gathered at the Concorde Conference Centre on 6 March to honour those who have demonstrated outstanding ingenuity and dedication.

TRIMTECH Therapeutics raises $31 million seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases.

Last week was a big one for UK life sciences, from the BIA Committee Summit shaping our sector’s future to major leadership changes at UKRI and NHS England. In this week’s update, I explore what these developments mean for our industry, alongside breakthroughs in AI, investment, and accessibility in healthcare.

In this blog, Albert Maguire - King, Media and Communications Executive at the BIA, outlines how the #BIGIMPACT campaign is utilising AI, data science, and tech talent to drive breakthroughs in biotech—ensuring the UK remains at the cutting edge of healthcare and scientific progress.

Rare Disease Day marks an important occasion to raise awareness of rare diseases and the need for action to support people and families living with these conditions.

Brainomix has announced a strategic partnership with Medtronic Neurovascular, a global leader in medical technology.

Stablepharma Ltd has secured a €2.5 million EIC Accelerator grant, recognizing its pioneering fridge-free pharmaceutical technology.

The data the biotech industry generates, consumes and shares is very often not only extremely sensitive (expensive to create, the product of some of the finest minds and technically focused facilities on the earth, in some cases connectable to the very fabric of humanity), it’s impossible to de-sensitise once lost to an attacker. 

Eleven early-stage companies working in oncology have started ‘Discovery Spark’, a free seven week development programme hosted by leading science and innovation campus Discovery Park, in Sandwich, Kent.

Apprenticeships offer a cost-effective way to develop talent, bridge skills gaps, and drive business growth—find out how they can deliver real ROI for your organisation.